Core Viewpoint - Gilead Sciences (GILD) is currently viewed as a more attractive undervalued stock option compared to Amgen (AMGN) based on various financial metrics and earnings outlook [1][7]. Valuation Metrics - GILD has a forward P/E ratio of 14.24, while AMGN's forward P/E is 15.10, indicating GILD may be undervalued relative to AMGN [5]. - The PEG ratio for GILD is 0.73, suggesting a favorable valuation when considering expected earnings growth, compared to AMGN's PEG ratio of 2.60 [5]. - GILD's P/B ratio stands at 7.26, significantly lower than AMGN's P/B ratio of 28.50, further supporting GILD's valuation as more attractive [6]. Earnings Outlook - GILD is experiencing an improving earnings outlook, which enhances its position in the Zacks Rank model, indicating a positive trend in earnings estimates [3][7].

Group 1 - JD.com, Inc. has a Zacks Rank of 1 (Strong Buy), indicating a more favorable earnings estimate revision activity compared to eBay, which has a Zacks Rank of 3 (Hold) [3] - Value investors typically analyze various traditional metrics to identify undervalued stocks, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] - JD has a forward P/E ratio of 8.74, significantly lower than eBay's forward P/E of 12.67, and a PEG ratio of 0.27 compared to eBay's 1.97, suggesting better value for JD [5] Group 2 - JD's P/B ratio stands at 1.53, while eBay's P/B ratio is much higher at 6.24, further supporting JD's superior valuation metrics [6] - Overall, JD has demonstrated stronger estimate revision activity and more attractive valuation metrics than eBay, making it a more appealing option for value investors [7]